Mind-NRG
Stage
Series B | DeadTotal Raised
$10MLast Raised
$8MAbout Mind-NRG
Mind-NRG is devoted to the development of NRG-101 in psychiatric and neurologic diseases. NRG-101 is a neurotrophic factor with disease modifying potential that naturally crosses the blood-brain barrier through a receptor-mediated transport to reach its target in the brain. NRG-101 is being developed to treat disorders such as Parkinson's disease, Alzheimer's disease and schizophrenia.
Loading...
Loading...
Mind-NRG Patents
Mind-NRG has filed 7 patents.
The 3 most popular patent topics include:
- clusters of differentiation
- neurological disorders
- proteins

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
5/23/2019 | 10/27/2020 | Clusters of differentiation, Neurological disorders, Transcription factors, Rare diseases, Proteins | Grant |
Application Date | 5/23/2019 |
---|---|
Grant Date | 10/27/2020 |
Title | |
Related Topics | Clusters of differentiation, Neurological disorders, Transcription factors, Rare diseases, Proteins |
Status | Grant |
Latest Mind-NRG News
Sep 4, 2013
By FinSMEs Mind-NRG , a Geneva, Switzerland-based company focusing on developing neuregulins to treat neurodegenerative diseases, closed its €6m (approximately $8m) Series B financing. Backers included new investor LRM and existing investor Index Ventures . Following the investment, Debora Dumont, Head of Health & Care at LRM will join the company’s board of directors. Created in 2010, Mind-NRG is investigating the use of neuregulins in treating a variety of neurological and psychiatric disorders. In particular, it is developing NRG-101 to treat the early-stages of neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease, as well as schizophrenia. The company plans to use the funding to continue to develop NRG-101’s neuroprotective effect in Parkinson’s disease, with the aim of advancing the compound to proof-of-concept studies in patients. FinSMEs
Mind-NRG Frequently Asked Questions (FAQ)
Where is Mind-NRG's headquarters?
Mind-NRG's headquarters is located at Rue de Jargonnant 2, Geneva.
What is Mind-NRG's latest funding round?
Mind-NRG's latest funding round is Series B.
How much did Mind-NRG raise?
Mind-NRG raised a total of $10M.
Who are the investors of Mind-NRG?
Investors of Mind-NRG include Index Ventures and LRM Capital.
Loading...
Loading...